This is a published notice on the Find a Tender service: https://www.find-tender.service.gov.uk/Notice/037488-2024

Award

Decision Support Service

Genomics England

F15: Voluntary ex ante transparency notice

Notice identifier: 2024/S 000-037488

Procurement identifier (OCID): ocds-h6vhtk-04bd2f

Published 20 November 2024, 11:23am

Section I: Contracting authority/entity

I.1) Name and addresses

Genomics England

One Canada Square, Canary Wharf

London

E14 5AB

Contact

Paul Nicholson

Email

paul.nicholson@genomicsengland.co.uk

Telephone

+44 2078825030

Country

United Kingdom

Region code

UKI - London

Internet address(es)

Main address

www.genomicsengland.co.uk

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title

Decision Support Service

Reference number

GeL-17/02

II.1.2) Main CPV code

• 72250000 - System and support services

II.1.3) Type of contract

Services

II.1.4) Short description

The provision of a Rare Disease Decision Support software solution for NGIS

II.1.6) Information about lots

This contract is divided into lots: No

II.1.7) Total value of the procurement (excluding VAT)

Value excluding VAT: £4,500,000

II.2) Description

II.2.3) Place of performance

NUTS codes

• UKI - London

II.2.4) Description of the procurement

In November 2018 Genomics England signed a contract with Congenica for the provision of interpretation services to support the NHS Genomic Medicine Service ("GMS") ("Decision Support Contract") which is due to expire on 30 November 2024

A contract amendment for the Rare Disease Decision Support Service contract under which Congenica will provide the services for the previously advised extension period of 6 months to 31 March 2025 and a further period of 12 months.

II.2.11) Information about options

Options: Yes

Description of options

Options to extend the term for a further 6 + 6 months.

II.2.13) Information about European Union Funds

The procurement is related to a project and/or programme financed by European Union funds: No

Section IV. Procedure

IV.1) Description

IV.1.1) Type of procedure

Award of a contract without prior publication of a call for competition in the cases listed below

• The procurement falls outside the scope of application of the regulations

Explanation:

Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract.

IV.1.8) Information about the Government Procurement Agreement (GPA)

The procurement is covered by the Government Procurement Agreement: Yes

Section V. Award of contract/concession

Contract No

GeL-17/02

Title

Decision Support Services

A contract/lot is awarded: Yes

V.2) Award of contract/concession

V.2.1) Date of conclusion of the contract

20 November 2024

V.2.2) Information about tenders

The contract has been awarded to a group of economic operators: No

V.2.3) Name and address of the contractor/concessionaire

Congenica

Wellcome Genome Campus

Cambridge

CB10 1DR

Country

United Kingdom

NUTS code

• UKH12 - Cambridgeshire CC

The contractor/concessionaire is an SME

Yes

V.2.4) Information on value of contract/lot/concession (excluding VAT)

Initial estimated total value of the contract/lot/concession: £4,500,000

Total value of the contract/lot/concession: £4,500,000

V.2.5) Information about subcontracting

The contract/lot/concession is likely to be subcontracted

Section VI. Complementary information

VI.3) Additional information

Genomics England will on 1 December 2024 enter into a contract amendment for the Decision Support Service Contract under which Congenica will provide the services for the previously advised extension period of 6 months to 31 March 2025 and a further period of 12 months with an option to extend for a further 6 + 6 months.

Genomics England takes the view that Regulation 72 (1) (b) applies to the variation to the Decision Support Contract because additional services from Congenica have become necessary but were not included in the original procurement of this contract but a change of contractor cannot be made at this time due to the bespoke technical specification of the product and it would also cause significant duplication of cost for Genomics England. The value of the variation is under 50% of the value of the Decision Support Contract.

NHS England has confirmed that a functioning decision support system for rare disease is essential to the success of the GMS for rare disease and no hiatus in these services is possible. Genomics England has very specific requirements for decision support as any product needs to fit in with its internal National Genomics Informatics System (NGIS) pipeline and no off the shelf product is available or viable without significant development. Given the background to Congenica development, an immediate termination would not only have led to a hiatus in service but would cause substantial inconvenience and duplication of costs should a new decision support provider be brought in.

Genomics England are in the process of developing a replacement solution.

VI.4) Procedures for review

VI.4.1) Review body

High Court

London

Country

United Kingdom